Stock Financial Ratios, Dividends, Split History

DVA / DaVita HealthCare Partners Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price73.47
Volume3,351,000.00
Market Cap ($M)13,060.32
Enterprise Value ($M)21,463.34
Book Value ($M)4,580.68
Book Value / Share26.25
Price / Book2.69
NCAV ($M)-4,452.23
NCAV / Share-25.51
Price / NCAV-2.88
Share Statistics
Common Shares Outstanding 182,000,000
Common Stock Shares Outstanding 182,462,278
Weighted Average Number Of Diluted Shares Outstanding 191,348,533
Weighted Average Number Of Shares Outstanding Basic 188,626,000
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.04
Return on Equity (ROE)0.18
Balance Sheet (mrq) ($M)
Assets18,942.37
Liabilities13,125.79
Quick Ratio2.90
Current Ratio2.94
Identifiers and Descriptors
CUSIP23918K108
Central Index Key (CIK)927066
Related CUSIPS
23918K908 23918K958

Split History

Stock splits are used by DaVita HealthCare Partners Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

DaVita's Big Insurance Problem

2018-06-18 seekingalpha
Editor's note: Seeking Alpha is proud to welcome Ethan Watkins as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » (7-0)

Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q1 2018 Update

2018-05-16 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to Berkshire Hathaway’s (NYSE:BRK.A) (NYSE:BRK.B) 13F stock portfolio on a quarterly basis. It is based on Warren Buffett’s regulatory 13F Form filed on 05/15/2018. Please visit our Tracking 10 Years Of Berkshire Hathaway's Investment Portfolio article series for an idea on how his holdings have progressed over the years and our previous update for the moves in Q4 2017. (712-8)

UPDATE 2-Four found guilty in insider trading case linked to U.S. health agency

2018-05-03 reuters
NEW YORK (Reuters) - Two partners at the hedge fund Deerfield Management and two others were found guilty on Thursday of charges stemming from what prosecutors have described as an insider trading scheme based on leaks from within a federal healthcare agency. (18-1)

UnitedHealth Group Incorporated Had a Bang-Up Quarter, And It’s Not Done Yet | InvestorPlace

2018-04-20 investorplace
UnitedHealth Group Incorporated (NYSE:UNH) was the second-largest healthcare company in the U.S. in 2016 by revenue, and that includes physician benefit management (PBMs) firms, drug stores, pharmaceutical firms and distributors. (97-0)

Static UnitedHealth Group Inc Stock Doesn’t Offer Much Upside | InvestorPlace

2018-04-18 investorplace
Thanks to the dramatic differences in approach between the current and prior presidential administrations, healthcare is an incredibly unpredictable sector. Nevertheless, if you’re UnitedHealth Group Inc (NYSE:UNH), you’ve got a tight handle on things. As one of the world’s biggest healthcare companies, UNH stock seems like a sure bet. (107-0)

CUSIP: 23918K108